PP
MYGN icon

Paloma Partners’s Myriad Genetics MYGN Stock Holding History

Paloma Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,744
Closed -$212K – 809
2024
Q3 		$212K Buy
+7,744
New +$210K 0.01% 956
2020
Q1 		– Sell
-16,855
Closed -$459K – 1783
2019
Q4 		$459K Buy
+16,855
New +$464K 0.01% 1459
2019
Q3 		– Sell
-8,400
Closed -$233K – 2164
2019
Q2 		$233K Sell
8,400
-11,422
-58% -$323K ﹤0.01% 1445
2019
Q1 		$658K Buy
+19,822
New +$603K 0.02% 934
2017
Q4 		– Sell
-8,200
Closed -$297K – 2170
2017
Q3 		$297K Sell
8,200
-21,421
-72% -$611K ﹤0.01% 1803
2017
Q2 		$766K Sell
29,621
-10,065
-25% -$214K 0.01% 1331
2017
Q1 		$762K Sell
39,686
-9,964
-20% -$177K 0.01% 1400
2016
Q4 		$828K Buy
+49,650
New +$898K 0.01% 1268

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Paloma Partners's MYGN Position: Q4 2024 in Review

Paloma Partners sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 7,744 shares — an estimated $212K sold.

Paloma Partners first reported a position in MYGN in Q4 2016 and held it in 8 quarters. The position peaked at $828K in Q4 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Paloma Partners reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 7,744 Myriad Genetics shares in Q4 2024, an estimated $212K.
  • Paloma Partners first reported a position in Myriad Genetics in Q4 2016 and held it in 8 quarters.
  • Paloma Partners's Myriad Genetics position peaked at $828K in Q4 2016.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.